Abiopharma

🔍 LO FRANCIS (Executive)

Company: Adaptive Biotechnologies Corp (ADPT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 3,125 shares of Common Stock at $3.99 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 319,103.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,125 shares of Common Stock at $16.08 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 315,978.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: By You Jin Lee (spouse) | shares_owned_after: 2,500.00
• Sold 3,125 shares of Stock Option (right to buy) at $3.99 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2034-03-04 | equity_swap_involved: 0 | shares_owned_after: 104,856.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
• F2: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.77 to $16.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
• F3: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.